Acton, Massachusetts-based Insulet touts Omnipod 5 as the number one insulin pump for new users in Europe. It remains the top ...

Abbott and Dexcom settled all patent lawsuits related to continuous glucose monitors (CGMs). The two competitors, who lead ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A ...

Insulet Corporation PODD recently made its Omnipod 5 automated insulin delivery system commercially available in five more ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...

Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains ...

In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on Dexcom (DXCM – Research Report), with a ...

Dexcom (Nasdaq:DXCM) today announced preliminary financial results with projections for significant sales growth in 2025.

DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...

First Hawaiian Bank grew its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 556.1% in the 4th quarter, according to ...